NASDAQ:XLRNAcceleron Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acceleron Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $98.59 -0.50 (-0.50 %) (As of 05/22/2020 04:00 PM ET) Add Compare Share Today's Range$96.77Now: $98.59▼$99.1650-Day Range$80.78MA: $94.80▼$105.1052-Week Range$37.01Now: $98.59▼$108.50Volume170,598 shsAverage Volume379,501 shsMarket Capitalization$5.31 billionP/E RatioN/ADividend YieldN/ABeta0.77 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAcceleron Pharma has received a consensus rating of Buy. The company's average rating score is 2.77, and is based on 11 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $111.85, Acceleron Pharma has a potential upside of 13.4% from its current price of $98.59.Amount of Analyst CoverageAcceleron Pharma has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.9 Community Rank Outperform VotesAcceleron Pharma has received 529 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAcceleron Pharma has received 368 “underperform” votes. (Add your “underperform” vote.)Community SentimentAcceleron Pharma has received 58.97% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote “Outperform” if you believe XLRN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAcceleron Pharma does not currently pay a dividend.Dividend GrowthAcceleron Pharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acceleron Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,658,025.00 in company stock.Percentage Held by InsidersOnly 2.50% of the stock of Acceleron Pharma is held by insiders.Percentage Held by Institutions86.17% of the stock of Acceleron Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Acceleron Pharma are expected to decrease in the coming year, from ($3.16) to ($3.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acceleron Pharma is -38.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acceleron Pharma is -38.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcceleron Pharma has a P/B Ratio of 12.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XLRN Previous Symbol CUSIPN/A CIK1280600 Webwww.acceleronpharma.com Phone617-649-9200Debt Debt-to-Equity Ratio0.04 Current Ratio15.15 Quick Ratio15.15Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$73.99 million Price / Sales71.73 Cash FlowN/A Price / Cash FlowN/A Book Value$7.69 per share Price / Book12.82Profitability EPS (Most Recent Fiscal Year)($2.38) Net Income$-124,860,000.00 Net Margins-182.31% Return on Equity-30.14% Return on Assets-27.01%Miscellaneous Employees173 Outstanding Shares53,830,000Market Cap$5.31 billion Next Earnings Date8/3/2020 (Estimated) OptionableOptionable NASDAQ:XLRN Rates by TradingView Receive XLRN News and Ratings via Email Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter. Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions How has Acceleron Pharma's stock been impacted by COVID-19 (Coronavirus)? Acceleron Pharma's stock was trading at $84.39 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XLRN stock has increased by 16.8% and is now trading at $98.59. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Acceleron Pharma? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 1 sell rating, 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Acceleron Pharma. When is Acceleron Pharma's next earnings date? Acceleron Pharma is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Acceleron Pharma. How were Acceleron Pharma's earnings last quarter? Acceleron Pharma Inc (NASDAQ:XLRN) issued its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.86) by $0.09. The biopharmaceutical company had revenue of $4.30 million for the quarter, compared to analysts' expectations of $5.26 million. Acceleron Pharma had a negative return on equity of 30.14% and a negative net margin of 182.31%. Acceleron Pharma's revenue was up 53.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.74) EPS. View Acceleron Pharma's earnings history. What price target have analysts set for XLRN? 13 analysts have issued 12-month price targets for Acceleron Pharma's stock. Their forecasts range from $71.00 to $137.00. On average, they expect Acceleron Pharma's share price to reach $111.85 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price. View analysts' price targets for Acceleron Pharma. What are Wall Street analysts saying about Acceleron Pharma stock? Here are some recent quotes from research analysts about Acceleron Pharma stock: 1. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (1/16/2020) 2. HC Wainwright analysts commented, "We are lowering our price target to $68 from $69 due to the discontinuation of ACE-083 for FSHD. Our $68 price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline, and estimated year-end cash." (9/17/2019) Has Acceleron Pharma been receiving favorable news coverage? Media coverage about XLRN stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acceleron Pharma earned a coverage optimism score of 1.5 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutAcceleron Pharma. Are investors shorting Acceleron Pharma? Acceleron Pharma saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 4,080,000 shares, an increase of 7.4% from the April 15th total of 3,800,000 shares. Based on an average daily trading volume, of 734,300 shares, the short-interest ratio is currently 5.6 days. Approximately 8.9% of the shares of the company are short sold. View Acceleron Pharma's Current Options Chain. Who are some of Acceleron Pharma's key competitors? Some companies that are related to Acceleron Pharma include NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BioNTech (BNTX), BIO-TECHNE (TECH), Qiagen (QGEN), Repligen (RGEN), Allogene Therapeutics (ALLO), argenx (ARGX), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA) and Ablynx (ABLYF). View all competitors. What other stocks do shareholders of Acceleron Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Incyte (INCY), Intel (INTC), NVIDIA (NVDA), Bausch Health Companies (BHC), Cisco Systems (CSCO), LogicBio Therapeutics (LOGC), Corcept Therapeutics (CORT) and FibroGen (FGEN). Who are Acceleron Pharma's key executives? Acceleron Pharma's management team includes the following people: Mr. Habib J. Dable, CEO, Pres & Director (Age 50)Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 76)Mr. Kevin F. McLaughlin, Sr. VP, CFO & Treasurer (Age 63)Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 59)Dr. John D. Quisel, Exec. VP, Chief Bus. Officer & Sec. (Age 48) What is Acceleron Pharma's stock symbol? Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN." Who are Acceleron Pharma's major shareholders? Acceleron Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.56%), Wellington Management Group LLP (3.61%), State Street Corp (2.76%), TimesSquare Capital Management LLC (1.87%), Cormorant Asset Management LP (1.53%) and Geode Capital Management LLC (1.28%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Ravindra Kumar and Sujay Kango. View institutional ownership trends for Acceleron Pharma. Which major investors are selling Acceleron Pharma stock? XLRN stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Bank of New York Mellon Corp, Eagle Asset Management Inc., Carillon Tower Advisers Inc., Foresite Capital Management III LLC, Foresite Capital Management II LLC, TimesSquare Capital Management LLC, and QVT Financial LP. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin, Ravindra Kumar, and Sujay Kango. View insider buying and selling activity for Acceleron Pharma. Which major investors are buying Acceleron Pharma stock? XLRN stock was bought by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Lord Abbett & CO. LLC, BlackRock Inc., Nuveen Asset Management LLC, Orbimed Advisors LLC, Eventide Asset Management LLC, Invesco Ltd., and Two Sigma Investments LP. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene, and Joseph S Zakrzewski. View insider buying and selling activity for Acceleron Pharma. How do I buy shares of Acceleron Pharma? Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Acceleron Pharma's stock price today? One share of XLRN stock can currently be purchased for approximately $98.59. How big of a company is Acceleron Pharma? Acceleron Pharma has a market capitalization of $5.31 billion and generates $73.99 million in revenue each year. The biopharmaceutical company earns $-124,860,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe. What is Acceleron Pharma's official website? The official website for Acceleron Pharma is www.acceleronpharma.com. How can I contact Acceleron Pharma? Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected] This page was last updated on 5/25/2020 by MarketBeat.com Staff
